NCT04124276

Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder

Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder: a Randomized,Placebo-controled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 284 (estimated)
• Sponsor: Guangzhou Psychiatric Hospital · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia. Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported to have neuroprotective effects. Animal studies suggested that LBP has neuroprotective effect on optic ganglion cells. In animal models of depression, LBP can improve depressive symptom by improving synaptic plasticity. However, its clinical effect remains to be studied. We will conduct a 6-week double-blind, randomized, placebo-con-trolled trial in patients with major depressive disorder (MDD). The purpose of this clinical trial is to investigate the efficacy of LBP in patients with MDD.

Conditions

• Major Depressive Disorder
• Depression
• Depressive Disorder

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Lycium barbarum polysaccharide	Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
DIETARY_SUPPLEMENT	Placebo	Placebo control group takes placebo (300mg/day) for 6 weeks.

Timeline

• Start date: 2019-11-01
• Primary completion: 2020-12-30
• Completion: 2021-06-01
• First posted: 2019-10-11
• Last updated: 2020-10-30

Locations

1 site across 1 country: China